

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5694587

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
Name		Execution Date
ELWHA LLC		08/29/2019
RECEIVING PARTY DATA		
Name:	THE INVENTION SCIENCE FUND II, LLC	
Street Address:	3150 139TH AVE SE	
City:	BELLEVUE	
State/Country:	WASHINGTON	
Postal Code:	98005	
PROPERTY NUMBERS Total: 21		
Property Type	Number	
Application Number:	14549763	
Application Number:	14549685	
Application Number:	14623722	
Application Number:	15178715	
Application Number:	14623759	
Application Number:	13374351	
Application Number:	13374353	
Application Number:	15924898	
PCT Number:	US2012070840	
Application Number:	14549726	
PCT Number:	US2017036521	
Application Number:	16256222	
PCT Number:	US2019022572	
Application Number:	16523664	
Application Number:	13804224	
Application Number:	15290043	
Application Number:	15498780	
PCT Number:	US2014023650	
Application Number:	16205556	
Application Number:	13826803	

PATENT

Property Type	Number
Application Number:	13827960

CORRESPONDENCE DATA

Fax Number: (425)679-0625

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 4254672325

Email: cori@intvenls.com

Correspondent Name: INVENTION SCIENCE FUND

Address Line 1: 3150 139TH AVE SE

Address Line 4: BELLEVUE, WASHINGTON 98005

NAME OF SUBMITTER:	ELIZABETH L. SCHUBERT
SIGNATURE:	/Elizabeth L. Schubert/
DATE SIGNED:	08/29/2019

Total Attachments: 4

source=Assignment_Elwha_to_ISF2#page1.tif

source=Assignment_Elwha_to_ISF2#page2.tif

source=Assignment_Elwha_to_ISF2#page3.tif

source=Assignment_Elwha_to_ISF2#page4.tif

ASSIGNMENT

WHEREAS, ELWHA LLC (hereinafter referred to as ASSIGNOR), having a post office address of 3150 - 139th Ave SE, Building 4, Bellevue, WA 98005, is the assigned owner of the entire right, title and interest in and to the patent applications listed in the table below (hereinafter collectively referred to as "Patents");

ASSIGNOR does hereby sell, assign, transfer, and convey unto The Invention Science Fund II, LLC, a Delaware limited liability company with offices located at 3150 139th Avenue SE, Bellevue, WA 98005 (hereinafter referred to as ASSIGNEE) all of Assignor's right, title, and interest in and to the Patents listed in the table below.

PATENT APPLICATIONS

Docket Number	Application Date	Application Number	Title
0810-002-002-DIV002	11/21/2014	14/549,763	Compositions and Methods Including Recombinant B Lymphocyte Cell Line Including an Exogenously Incorporated Nucleic Acid Expressing an Exogenous Membrane Immunoglobulin Reactive to a First Antigen and Including an Endogenous Gene Expressing an Endogenous Secreted Immunoglobulin Reactive to a Second Antigen
0810-002-002-C00001	11/21/2014	14/549,685	Compositions and Methods Including Recombinant B Lymphocyte Cell Line Including an Exogenously Incorporated Nucleic Acid Expressing an Exogenous Membrane Immunoglobulin Reactive to a First Antigen and Including an Endogenous Gene Expressing an Endogenous Secreted Immunoglobulin Reactive to a Second Antigen
0810-002-003-DIV001	2/17/2015	14/623,722	Compositions and Methods Including Recombinant B Lymphocyte Cell Line Including at Least One Endogenous Gene Expressing at Least One Endogenous Membrane Immunoglobulin Reactive To a First Antigen and Including at Least One Exogenously Incorporated Nucleic Acid Expressing At Least One Exogenous Secreted Immunoglobulin Reactive to a Second Antigen

Docket Number	Application Date	Application Number	Title
0810-002-002-CIP001	6/10/2016	15/178,715	Compositions and Methods Including Cytotoxic B Lymphocyte Cell Line Expressing Exogenous Membrane Immunoglobulin Different from Secreted Immunoglobulin
0810-002-002-EP0001	12/20/2012	12859056.9	Compositions and Methods Including B Lymphocyte Cell Line Expressing Membrane Immunoglobulin Different from Secreted Immunoglobulin
0810-002-003-DIV002	2/17/2015	14/623,759	Compositions and Methods Including Recombinant B Lymphocyte Cell Line Including at Least One Endogenous Gene Expressing at Least One Endogenous Membrane Immunoglobulin Reactive to a First Antigen and Including at Least One Exogenously Incorporated Nucleic Acid Expressing At Least One Exogenous Secreted Immunoglobulin Reactive to a Second Antigen
0810-002-002-000000	12/22/2011	13/374,351	Compositions and Methods Including Recombinant B Lymphocyte Cell Line Including an Exogenously Incorporated Nucleic Acid Expressing an Exogenous Membrane Immunoglobulin Reactive to a First Antigen and Including an Endogenous Gene Expressing an Endogenous Secreted Immunoglobulin Reactive to a Second Antigen
0810-002-003-000000	12/22/2011	13/374,353	Compositions and Methods Including Recombinant B Lymphocyte Cell Line Including At Least One Endogenous Gene Expressing At Least one Endogenous Membrane Immunoglobulin Reactive to a First Antigen and Including At Least One Exogenously Incorporated Nucleic Acid Expressing at Least One Exogenous Secreted Immunoglobulin Reactive to a Second Antigen
0810-002-002-CP1CP1	3/19/2018	15/924,898	Compositions and Methods for Modified B Cells Expressing Reassigned Biological Agents
0810-002-002-PCTCMB	12/20/2012	PCT/US2012/070840	Compositions and Methods Including B Lymphocyte Cell Line Expressing Membrane Immunoglobulin Different from Secreted Immunoglobulin
0810-002-002-DIV001	11/21/2014	14/549,726	Compositions and Methods Including Recombinant B Lymphocyte Cell Line Including an Exogenously Incorporated Nucleic Acid Expressing an Exogenous Membrane Immunoglobulin Reactive to a First Antigen and Including an Endogenous Gene Expressing an Endogenous Secreted Immunoglobulin Reactive to a Second Antigen

Docket Number	Application Date	Application Number	Title
0810-002-002-PCTCP1	6/8/2017	PCT/US2017/036521	Compositions and Methods Including B Lymphocyte Cell Line Expressing Membrane Immunoglobulin Different from Secreted Immunoglobulin and Cytolytic Function
0810-002-002-CN0CP1	6/8/2017	201780047988.9	Compositions and Methods Including B Lymphocyte Cell Line Expressing Membrane Immunoglobulin Different from Secreted Immunoglobulin and Cytolytic Function
0810-002-002-EP0CP1	6/8/2017	17811004.5	Compositions and Methods Including B Lymphocyte Cell Line Expressing Membrane Immunoglobulin Different from Secreted Immunoglobulin and Cytolytic Function
0810-002-002-CP1DV1	1/24/2019	16/256,222	Compositions and Methods Including Cytotoxic B Lymphocyte Cell Line Expressing Exogenous Membrane Immunoglobulin Different from Secreted Immunoglobulin
0810-002-002-WOCP1	3/15/2019	PCT/US2019/022572	Compositions and Methods for Modified B Cells Expressing Reassigned Biological Agents
0810-002-002-CP1CPC	7/26/2019	16/523,664	Compositions and Methods for Modified B Cells Expressing Reassigned Biological Agents
0412-004-001-000000	3/14/2013	13/804,224	Compositions, Methods, and Computer Systems Related to Making and Administering Modified T Cells
0412-004-001B-C00001	10/11/2016	15/290,043	Compositions, Methods, and Computer Systems Related to Making and Administering Modified T Cells
0412-004-001B-C1C001	4/27/2017	15/498,780	Compositions, Methods, and Computer Systems Related to Making and Administering Modified T Cells
0412-004-001-EP0001	3/11/2014	14773595.5	Compositions, Methods, and Computer Systems Related To Making and Administering Modified T Cells
0412-004-001-PCTCMB	3/11/2014	PCT/US2014/023650	Compositions, Methods, and Computer Systems Related To Making and Administering Modified T Cells
0412-004-001B-C1C1C1	11/30/2018	16/205,556	Compositions, Methods, and Computer Systems Related to Making and Administering Modified T Cells
0412-004-001A-000000	3/14/2013	13/826,803	Compositions, Methods, and Computer Systems Related To Making and Administering Modified T Cells
0412-004-001B-000000	3/14/2013	13/827,960	Compositions, Methods, and Computer Systems Related To Making and Administering Modified T Cells

WHEREAS, The Invention Science Fund II, LLC (hereinafter referred to as ASSIGNEE), a limited liability corporation of the State of Delaware, having a place of business at 3150 - 139th Ave SE, Building 4, Bellevue, WA 98005, is desirous of acquiring the entire right, title and interest in and to the Patents;

NOW, THEREFORE, in consideration of One Dollar (\$1.00) and for other good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNOR hereby sells, assigns and transfers unto said ASSIGNEE the entire right, title and interest in and to said Patent and in any and all reissues and reexaminations thereof. Said Patent to be held and enjoyed by ASSIGNEE and its successors and assigns for their use and benefit and of their successors and assigns as fully and entirely as the same would have been held and enjoyed by ASSIGNOR had this assignment, transfer and sale not been made. ASSIGNOR hereby authorizes and requests the Commissioner of Patents and Trademarks to issue said Patent to ASSIGNEE. ASSIGNOR agrees to execute all instruments and documents required for litigation regarding said letters patent, or for the purpose of protecting title to said invention or letters patent therefor.

8/29/2019

Date

Elizabeth Schubert

Elizabeth L. Schubert